RxDoctor Payments Data

Jessica Gomez, MD

Ophthalmology · Temecula, CANPI 1790041804

Payments from drug & device makers

$40,051in general payments, 2019–2025

Across 98 payments — averaging $408.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$37K
  • Alcon$546
  • Mallinckrodt Hospital Products Inc.$490
  • Bausch & Lomb Americas Inc.$440
  • Sight Sciences, Inc.$339
  • Regeneron Healthcare Solutions, Inc.$307
  • plus $1K from 12 others

What the payments were for

  • Consulting fees$1,37529%
  • Food & beverage$3,40071%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,051 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$332,008
Medicare patients
634
Services billed
2,560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine57$46,338
RocklatanNetarsudil Mesylat/Latanoprost92$34,477
LumiganBimatoprost36$16,783
XiidraLifitegrast17$11,030
SimbrinzaBrinzolamide/Brimonidine Tart39$8,895
VyzultaLatanoprostene Bunod29$8,777
Cyclosporine16$7,326
Latanoprost318$5,341
RhopressaNetarsudil Mesylate15$5,039
Prednisolone Acetate142$4,210
Brimonidine Tartrate97$2,832
CombiganBrimonidine Tartrate/Timolol11$2,162
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat115$2,128
ErythromycinErythromycin Base155$1,606
Ofloxacin87$857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$255$65,282104 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$440$19,80746 claims
AlconSimbrinza$546$8,89539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Temecula

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →